On June 24, 2020 Xenocor, Inc., a privately held company focused on identifying, developing and commercializing innovative and differentiated endoscopes to address significant unmet needs in making minimally invasive approaches more accessible at a lower cost, reported that the United States Patent and Trademark Office (USPTO) is scheduled to issue Xenocor U.S. Patent No. 10,702,128 on July 7, 2020 (Press release, Xencor, JUN 24, 2020, View Source [SID1234561452]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This newly allowed patent is the latest U.S. patent to issue in connection with the Xenoscope Single-use Laparoscopic System and provides valuable protection for materials used in the disposable scope that reduce fogging and improve the clarity of the resulting images provided by the system.
"We are extremely pleased with the continued development of the patent portfolio. This new issuance continues to expand the breadth and depth of our Xenoscope intellectual property portfolio covering numerous key features," said Evan Kelso, CEO of Xenocor.
Recently, clinical adoption of single-use endoscopes has seen significant increases in the Global marketplace with CAGR of 18.7% through 2025. The volatility of the Covid-19 pandemic has accelerated the demand for single use surgical endoscopes and will continue as innovations like this come to market with the triple-aim in mind of improving care, improving the health of populations and reducing the cost of healthcare.
Demonstration video of the product in live use can be viewed here: View Source